Improving rAAV production and purification: towards the definition of a scaleable process.
Numerous in vivo studies have demonstrated that recombinant AAV-2 vectors (rAAV-2) can efficiently transduce many tissues and lead to stable gene expression 12. These encouraging results have led to a rapid development of clinical trials involving the use of rAAV-2 vectors 3. However, the obtainment of large-scale rAAV-2 vector stocks for clinical assay is still hampered by the conventional production and purification methods that are not efficient and difficult to scale up. This review will describe the current methods available for rAAV-2 vector production and purification and show the advancements achieved, in particular in our group, to develop new scalable procedures, suiting GMP requirements.
INSERM ERM 0105, CHU-Hôtel Dieu, Bât. Jean Monnet, 30 Av. Jean Monnet, 44035 Nantes, France.
Véronique
V
Blouin
Nicole
N
Brument
Estelle
E
Toublanc
Isabelle
I
Raimbaud
Philippe
P
Moullier
Anna
A
Salvetti
D000818:Animals; D000229:Dependovirus / Q000302:isolation & purification; D005822:Genetic Vectors / Q000302:isolation & purification; D006367:HeLa Cells; D006801:Humans; D014161:Transduction, Genetic